NWK Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

NWK Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,200	Closed	-$12K	–	107
2021 Q1	$12K	Buy	+1,200	New	+$12.4K	0.01%	155

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

NWK Group's BCRX Position: Q2 2021 in Review

NWK Group sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2021, closing a stake of 1,200 shares — an estimated $12K sold.

NWK Group first reported a position in BCRX in Q1 2021 and held it in 1 quarter. The position peaked at $12K in Q1 2021. 195 funds tracked by Wall St. Rank hold BCRX as of Q2 2021.

NWK Group reported no remaining BioCryst Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
NWK Group sold 1,200 BioCryst Pharmaceuticals shares in Q2 2021, an estimated $12K.
NWK Group first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 1 quarter.
NWK Group's BioCryst Pharmaceuticals position peaked at $12K in Q1 2021.
195 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2021.

Based on NWK Group's 13F filing for Q2 2021, filed 16 Aug 2021.